Our aim has been to develop potent, small molecule selective regulators of EPAC1 activity to determine the role of EPAC1 in the control of vascular inflammation and cardiovascular disease by cyclic AMP. This evidence concerns the gene RAPGEF3 and cardiovascular disorder.